The hypophosphatemic (Hyp) mouse, a murine homologue of human X-linked hypophosphatemic rickets, is characterized by renal defects in brush border membrane phosphate transport and vitamin %3 metabolism. The present study was undertaken to examine whether elevated renal 25-hydroxyvitamin D3-24-hydroxylase 
Introduction
The hypophosphatemic (Hyp)' mouse, a murine homologue of X-linked hypophosphatemia in man, is characterized by A preliminary report of this work was presented to the American Society of Bone and Mineral Research in Indianapolis, IN, June 1987. hypophosphatemia, rickets, and a specific renal defect in Na+-dependent phosphate transport at the brush border membrane (1) (2) (3) . Recent studies have demonstrated that the regulation of renal 25-hydroxyvitamin D3 [25(OH)D3] metabolism is also impaired in the X-linked Hyp mouse (4) (5) (6) (7) (8) (9) (10) (11) (12) . Mutant mice exhibit abnormal renal synthesis of 1,25-dihydroxyvitamin D3 [1, 25(OH) 2D3] in response to phosphate deprivation (4-6), PTH infusion (7), calcium restriction (7, 8) , and vitamin D deficiency (9, 10) . Moreover, the renal synthesis of 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] is significantly elevated in Hyp mice when compared with normal littermates (9, 11, 12) .
Although 24,25(OH)2D3 is the major renal metabolite produced by vitamin D-replete animals with normal calcium and phosphorus intake, its precise biological function is poorly understood. Accordingly, the significance of elevated renal mitochondrial 25(OH)D3-24-hydroxylase (24-hydroxylase) activity in Hyp mice (9, 11, 12) and its contribution to the mutant phenotype are not clearly established. Recent studies have demonstrated that 24-hydroxylase serves the catabolism of 1,25(OH)2D3 in intestine, kidney, and perhaps other target tissues by converting 1,25(OH)2D3 to the biologically inactive metabolite, 1 ,24,25-trihydroxyvitamin D3 [1 ,24,25(OH)3D31 (13, 14) . The latter serves as a precursor for the synthesis of 24-oxo-1 ,25-dihydroxyvitamin D3 [24-oxo-1,25(OH)2D3] (13, 14) , which is then hydroxylated at position C-23, yielding 24-oxo-1,23,25-trihydroxyvitamin D3 [24-oxo-l ,23,25(OH)3D3] (13, 14) . Recently, it has been demonstrated that in rat kidney the metabolite 24-oxo-1,23,25(OH)3D3 undergoes oxidative side chain cleavage to yield 1,23-dihydroxy-24,25,26,27-tetranor vitamin D3 (15) . This side chain cleaved metabolite may be converted (15) to the final inactivation product of 1 ,25(OH)2D3, namely 1 a-OH-24,25,26,27-tetranor-23-COOH-D3 (calcitroic acid) (16) .
In view of the importance of the side chain oxidation pathway in the degradation of 1,25(OH)2D3 (13) (14) (15) (16) 0.99% phosphorus, and 4.41 IU vitamin D3/g. Mice were killed at 3-4 mo of age by decapitation.
Renal metabolism of vitamin D3 metabolites. Mitochondria were prepared from renal cortex of individual or groups of mice according to the method of Vieth and Fraser (17) . In our standard assay procedure, aliquots (1 ml) of oxygenated mitochondria containing -1-2 mg protein in 125 mM KCI, 20 mM Hepes, 10 mM malic acid, 2 mM MgSO4, 1 mM dithiothreitol, and 0.25 mM EDTA, adjusted to a pH of 7.42 were incubated at 25°C with 500 nM 3H-1,25(OH)2D3 (-200 cpm/pmol) for 5-15 min as described previously (9, 10). To estimate kinetic parameters, mitochondria were incubated under initial rate conditions with 3H-1,25(OH)2D3 (2-500 nM) or 3H-25(OH)D3 (20-2,000 nM) and enzyme activity was estimated by the sum of the three products synthesized. Reaction mixtures in which boiled mitochondria were incubated with 3H-substrate at each concentration examined served as background in the quantitation of product formation. The reactions were stopped by the addition of 3.75 ml chloroform-methanol (1:2) and samples were stored at -20°C under N2 until extraction. 3H-Vitamin D3 metabolites were purchased from Amersham, Oakville, Ontario, Canada, and New England Nuclear, Boston, MA. Crystalline 25(OH)D3 and 1,25(OH)2D3 were gifts from Hoffman-La Roche Ltd., Etobicoke, Ontario, Canada.
Extraction and assay ofvitamin D3 metabolites. Extraction of reaction mixtures was performed as described by Bligh and Dyer (18) . Recovery of 3H-label from incubations with either intact or boiled mitochondria (where no significant conversion of substrate is apparent) was similar and ranged from 85 to 95%, indicating that all reaction products could be accounted for under the conditions of our experiments. Because the 3H-vitamin D3 substrates used in the present study were labeled in the C-26 and C-27 positions, we would not detect the production of 3H-labeled side chain cleavage products from 1,25(OH)2D3 and 25(OH)D3, i.e., 1,23(OH)2-24,25,26,27-tetranor-D3 and 23(OH)24,25,26,27-tetranor-D3. However, at high substrate concentrations where products were detectable by ultraviolet absorption, no evidence was obtained for the formation of unlabeled side chain cleavage products. Note that recovery of 3H-label with intact mitochondria fell to 60-80% of that from boiled mitochondria in those reaction mixtures containing 2 nM 1,25(OH)2D3. Accordingly, kinetic parameters for side chain oxidation of 1,25(OH)2D3 were estimated both without and with the data obtained at 2 nM substrate. Exclusion of the data derived at 2 nM 1,25(OH)2D3 did not significantly alter the kinetic parameters that were estimated by the Eadie-Hofstee transformation. The estimated kinetic constants are a measure of the first reaction in the sequence 1,25(OH)2D3 -0 1,24,25(OH)3D3 -* 24-oxo-1,25(OH)2D3 -* 24-oxo-1,23,25(OH)3D3.
Vitamin D3 metabolites were separated on Zorbax CN or SIL as described by Jones (19, 20) . The identity of products was confirmed by co-chromatography with standards authenticated by mass spectrometry.
Statistical methods. Effect of genotype on metabolite production was analyzed by Student's t test.
Results
The separation of side chain oxidation products, derived from incubation of renal mitochondria with 3H-1,25(OH)2D3, is illustrated in Fig. 1 . The identity of each metabolite was confirmed by comparison with standards authenticated by mass spectrometry. A clear separation of 3H-1,25(OH)2D3 (peak 2), 24-oxo-1,25(OH)2D3 (peak 3), 24-oxo-1,23,25(OH)3D3 (peak 4), and 1,24,25(OH)3D3 (peak 5) was achieved on Zorbax SIL (Fig. 1) . The material which eluted in peak 1 represents an impurity in the 3H-1,25(OH)2D3 substrate and was present in all mitochondrial extracts, irrespective of whether mitochondria were intact or boiled. from normal mice (n = 7, SEM < 2%). In spite of a twofold increase in the rate of product formation by renal mitochondria from Hyp mice, the relative proportion ofeach metabolite was identical to that of normal mice. To understand the mechanism for the observed increase in 1,25(OH)2D3 catabolism by Hyp mouse kidney, the effect of substrate concentration on side chain oxidation was examined. We estimated enzyme activity, at each concentration of 1,25(OH)2D3, from the sum of the three products synthesized per milligram protein under initial rate conditions (see Total, Fig. 2) . Fig. 3 A shows (Table I) .
We also examined the side chain oxidation of 25 mice. Total enzyme activity is saturable in both genotypes and is significantly higher in Hyp/Y mice (Fig. 3 B) . Kinetic parameters, estimated as described above are shown in Table I (Fig. 2) . We suggest that increased catabolism of 1,25(OH)2D3 may play an important role in the pathophysiology ofboth murine and human X-linked hypophosphatemic rickets.
Side chain oxidation is a major catabolic pathway for 1,25(OH)2D3 in kidney (13, 15) and intestine (13, 14) under physiological conditions. The pathway involves sequential 24-hydroxylation, 24-oxidation, 23-hydroxylation, and eventual side chain cleavage of 1,25(OH)2D3. It provides an important mechanism whereby the physiological concentration of hormone, and thus the biological response, can be controlled. Accordingly, increased renal side chain oxidation of 1,25(OH)2D3 in Hyp mice would decrease the effective concentration of 1,25(OH)2D3 available for biological action in the kidney and perhaps other target tissues. Our demonstration of increased renal catabolism of 1,25(OH)2D3 may account, in part, for the inappropriate plasma levels of 1,25(OH)2D in Hyp mice (4) and in patients with X-linked hypophosphatemia (21, 22) , and may explain why supraphysiological doses of 1,25(OH)2D3 (and phosphate supplementation) are required for correction of bone lesions in these patients (23) . Moreover, our results are consistent with the previous demonstration that plasma clearance of high doses of exogenous 1,25(OH)2D3 is more rapid in Hyp mice than in normal littermates (24). Whether other target tissues in the mutant strain exhibit increased degradation of the vitamin D hormone requires further study.
Increased renal catabolism of 1,25(OH)2D3 by the side chain oxidation pathway may also account, in part, for inappropriate renal production of 1,25(OH)2D3 in Hyp mice compared with normal mice with comparable hypophosphatemia, achieved by feeding a low phosphate diet (5, 6) . It is well documented that phosphate deprivation is associated not only with a stitnulation in renal l-hydroxylase activity and vitamin D hormone production (25, 26) , but also with a marked inhibition of renal 24-hydroxylase activity (11, 25 (5, 6) . Note that increased side chain oxidation cannot account for the blunted 1 -hydroxylase response to vitamin D and calcium deficiency reported in Hyp mice (9, 10), since these experiments were performed under conditions where renal 24-hydroxylase is completely inhibited (9, 12) . Moreover, no evidence for the production of 1,24,25(OH)3D3 was found in vitamin D and calcium-deprived Hyp mice (12) .
The present study demonstrates that renal side chain oxidation of both 25(OH)D3 and 1,25(OH)2D3 is increased in the Hyp mouse relative to normal littermates and that the relative proportion of products synthesized from 1,25(OH)2D3 is similar in both genotypes. Other studies have shown, in rat and mouse, that renal side chain oxidation of both 25(OH)D3 and 1,25(OH)2D3 can also be increased by prior treatment with vitamin D3 or 1,25(OH)2D3 (13, 20, 27, 28) . These findings raise two questions:
(i) Are the three reactions in this pathway, namely 24-hydroxylation, 24-oxidation, and 23-hydroxylation, mediated by a single enzyme or by three distinct enzymes whose regulation is coordinated?
(ii) Are 25(OH)D3 and 1,25(OH)2D3 both metabolized by the same enzyme system? The demonstration that catabolism of both substrates is increased by the Hyp mutation (Table I) as well as by prior treatment with 1,25(OH)2D3 (13, 20, 27, 28) , suggests the existence of one multienzyme complex that mediates destruction of both 25(OH)D3 and 1,25(OH)2D3. Clearly, information regarding the molecular structure and the regulation of the enzyme(s) involved in the renal mitochondrial side chain oxidation pathway will require further study. As is the case for the enzymes that catalyze the production of 24,25(OH)2D3 and 1,25(OH)2D3, the side chain oxidation system may involve cytochrome P-450 mixed function oxidases that are tightly associated with the inner mitochondrial membrane of renal proximal tubular cells (29) . Direct evidence for one cytochrome P-450 enzyme exhibiting several catalytic activities has been presented in the adrenal cortex (30) . The 
